Journal
CUREUS JOURNAL OF MEDICAL SCIENCE
Volume 13, Issue 1, Pages -Publisher
SPRINGERNATURE
DOI: 10.7759/cureus.12482
Keywords
pirfenidone
Categories
Ask authors/readers for more resources
In addition to its beneficial effects in IPF, PFD has effectively improved survival rates and reduced respiratory-related hospitalizations in patients with acute exacerbation of IPF. PFD has also shown improvement in vital capacity in patients with chronic hypersensitive pneumonitis, and demonstrated anti-fibrotic effects in systemic sclerosis-associated interstitial lung disease.
Fibrosis is the result of chronic inflammation and is known to pathologically occur in many organs and systems. Pirfenidone (PFD) is an anti-fibrotic known for its use in idiopathic pulmonary fibrosis (IPF). In addition to being an anti-fibrotic, it acts as an anti-inflammatory and antioxidant as well. There have been studies on PFD in other diseases, some clinical and others preclinical. We have compiled and reviewed them to highlight just how widespread PFD use could be. Among many benefits of PFD in IPF, PFD has effectively improved patients' survival in those who had an acute exacerbation of IPF and has reduced respiratory related hospitalization, among few others. PFD also has shown an improvement in vital capacity in patients with chronic hypersensitive pneumonitis. Also, it has demonstrated anti-fibrotic effects in systemic sclerosis-associated interstitial lung disease. In other diseases outside the lungs, PFD has reversed insulin resistance and proven to be effective in non-alcoholic steatohepatitis (NASH). It has prevented blindness post-alkali injury to the eye and has proven to decrease the proliferation of mesothelioma cells, just to name a few. This review encourages further research in connection with PFD and its use in other diseases and PFD pros in IPF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available